Skip to content
Karyopharm to Participate at Upcoming Investor Conferences

NEWTON, Mass., Sept. 5, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in the following investor conferences in September:

H.C. Wainwright 25th Annual Global Investment Conference
Format: Podium presentation
Date: Monday, September 11, 2023
Time: 12:30 p.m. ET

Morgan Stanley 21st Annual Global Healthcare Conference
Format: Fireside chat
Date: Tuesday, September 12, 2023
Time: 5:30 p.m. ET

Baird 2023 Global Healthcare Conference
Format: Fireside chat
Date: Wednesday, September 13, 2023
Time: 2:00 p.m. ET

A live webcast of the presentation and fireside chats, along with accompanying slides, can be accessed under "Events & Presentations" in the Investor section of the Company's website,, and will be available for replay for 90 days following each presentation. 

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies. Since its founding, Karyopharm has been an industry leader in oral Selective Inhibitor of Nuclear Export (SINE) compound technology, which was developed to address a fundamental mechanism of oncogenesis: nuclear export dysregulation. Karyopharm's lead SINE compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications and has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including Europe and the United Kingdom (as NEXPOVIO®) and China. Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic neoplasms and myelofibrosis. For more information about our people, science and pipeline, please visit, and follow us on Twitter at @Karyopharm and LinkedIn.

SOURCE Karyopharm Therapeutics Inc.

For further information: Investors: Elhan Webb, CFA, Senior Vice President, Investor Relations, 617.658.0600,; Media:Stacy Nobles, Head of Corporate Communications, 617.658.06540,
I agree to the storing and processing of my personal data by Karyopharm as described in the Privacy Policy and to the Terms of Use . I agree to receive communications from Karyopharm and understand that I can unsubscribe at any time.